Edition:
India

Melinta Therapeutics, Inc. (MLNT.OQ)

MLNT.OQ on NASDAQ Stock Exchange Global Select Market

7.20USD
9:09pm IST
Change (% chg)

$-0.25 (-3.36%)
Prev Close
$7.45
Open
$7.45
Day's High
$7.45
Day's Low
$7.20
Volume
19,539
Avg. Vol
86,862
52-wk High
$24.25
52-wk Low
$5.20

Chart for

About

Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide therapeutic solutions. The Company’s lead product is Baxdela, an antibiotic approved by the United States food and drug administration (FDA) for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). The... (more)

Overall

Beta: 1.07
Market Cap(Mil.): $166.71
Shares Outstanding(Mil.): 52.51
Dividend: --
Yield (%): --

Financials

BRIEF-Melinta Therapeutics Prices Public Offering Of 22.0 Mln Shares At $5/Share

* MELINTA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

24 May 2018

BRIEF-Melinta Therapeutics Announces Proposed Offering Of Common Stock

* MELINTA THERAPEUTICS ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

22 May 2018

BRIEF-Melinta Therapeutics Q1 Loss Per Share $0.95

* MELINTA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

09 May 2018

BRIEF-Melinta Therapeutics Q4 Loss Per Share $1.48

* MELINTA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

13 Mar 2018

BRIEF-Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application For Delafloxacin In Europe

* MELINTA THERAPEUTICS PARTNER, MENARINI GROUP, SUBMITS MARKETING AUTHORIZATION APPLICATION FOR DELAFLOXACIN IN EUROPE

08 Mar 2018

BRIEF-Melinta Therapeutics Launches Antibiotic Baxdela In U.S.

* MELINTA THERAPEUTICS LAUNCHES ANTIBIOTIC BAXDELA™ (DELAFLOXACIN) IN THE UNITED STATES Source text for Eikon: Further company coverage:

29 Jan 2018

BRIEF-Melinta Therapeutics Files For Mixed Shelf Offering Of Upto $150 Million

* MELINTA THERAPEUTICS INC FILES FOR MIXED SHELF OFFERING OF UPTO $150 MILLION - SEC FILING Source text - http://bit.ly/2DSYZpm Further company coverage:

27 Jan 2018

BRIEF-Melinta Therapeutics Says ‍Partner Commenced New Program For Topical Formulation Of Radezolid, In Preparation For Submitting IND Application To FDA

* MELINTA THERAPEUTICS - ‍PARTNER COMMENCED NEW PROGRAM FOR A TOPICAL FORMULATION OF RADEZOLID, IN PREPARATION FOR SUBMITTING AN IND APPLICATION TO FDA Source text for Eikon: Further company coverage:

18 Jan 2018

BRIEF-Melinta Therapeutics Files For Resale Of Up To 6.9 Mln Shares By Selling Stockholders

* MELINTA THERAPEUTICS INC FILES FOR RESALE OF UP TO 6.9 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING‍​ Source text: (http://bit.ly/2EqugN6) Further company coverage:

10 Jan 2018

BRIEF-Melinta Therapeutics Files For Resale Of Up To 3.3 Mln Shares By Selling Stockholder

* MELINTA THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDER - SEC FILING Source text for Eikon: (http://bit.ly/2CO48LP) Further company coverage:

10 Jan 2018

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,758 +2.00
Johnson & Johnson (JNJ.N) $122.87 +1.42
Pfizer Inc. (PFE.N) $36.56 +0.26
Roche Holding Ltd. (ROG.S) CHF216.45 --
Roche Holding Ltd. (RO.S) CHF223.60 +4.00
Abbott Laboratories (ABT.N) $62.24 +0.49
Bayer AG (BAYGn.DE) €98.84 +2.45
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €69.01 +1.30
AstraZeneca plc (AZN.L) 5,229.00 -26.00

Earnings vs. Estimates